NASDAQ:NVNO enVVeno Medical Q2 2025 Earnings Results & Report $5.77 -0.18 (-3.03%) Closing price 04:00 PM EasternExtended Trading$5.76 0.00 (-0.09%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. enVVeno Medical missed analyst earnings expectations in its Q2 2025 results, released July 31, 2025. The company reported EPS of -$11.55 versus the -$9.80 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateJuly 31, 2025TimeBefore Market Opens enVVeno Medical EPS ResultsActual EPS-$11.55Consensus EPS -$9.80Beat/MissMissed by -$1.75One Year Ago EPSN/AEPS Beat Rate2 of last 6 quartersenVVeno Medical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile enVVeno Medical Q2 2025 Earnings FAQ Did enVVeno Medical beat earnings estimates for Q2 2025? enVVeno Medical (NASDAQ:NVNO) reported earnings of -$11.55 per share for Q2 2025, missing the consensus estimate of -$9.80. The report was announced on Thursday, July 31, 2025. enVVeno Medical Earnings HeadlinesenVVeno Medical to present its enVVE System at annual TCTNovember 2, 2026 | tipranks.comenVVeno Medical Corporation: enVVeno Medical Reports Third Quarter 2026 Financial Results and Prepares to Treat First Patients in FDA-Approved TAVVE Pivotal StudyOctober 30, 2026 | finanznachrichten.deI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 17 at 1:00 AM | Behind the Markets (Ad)enVVeno Medical Releases New Episode of "WTF" Video Series Featuring CEO Rob BermanOctober 21, 2026 | finance.yahoo.comenVVeno Medical Corporation: enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal TrialOctober 2, 2026 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video SeriesSeptember 16, 2026 | finanznachrichten.deSee More enVVeno Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like enVVeno Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enVVeno Medical and other key companies, straight to your email. Email Address About enVVeno MedicalenVVeno Medical (NASDAQ:NVNO) is a medical-device company developing treatments for chronic venous disease, with a focus on deep venous chronic venous insufficiency. This condition can occur when valves in the leg’s deep veins do not function properly, impairing blood flow back to the heart. The company’s lead product, VenoValve, is a bioprosthetic valve designed to restore valve function in affected deep veins. enVVeno has also described a transcatheter valve program, enVVe, intended to provide a less invasive approach to treating the condition. Previously known as Hancock Jaffe Laboratories, the company adopted the enVVeno Medical name in 2021. It is based in Irvine, California, and its development efforts are directed primarily toward the U.S. market.View enVVeno Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.